Singapore, Dec. 1 -- SAI Parenterals Limited (SPL), an India-based pharmaceutical formulation company, has announced the acquisition of a 74.6% controlling stake in Noumed Pharmaceuticals, an Adelaide-based pharmaceutical company, for an aggregate sum of Rs 125 crore.

SAI Parenterals has filed its IPO DRHP with SEBI in September 30, 2025 - the offer, with a face value of Rs 5 per equity share, comprises a fresh issue of up to Rs 285 crore and an offer for sale of up to 3,500,000 equity shares by existing shareholders.

Noumed Pharmaceuticals, a company with AUD 60 million in revenue, is a supplier of private label over the counter (OTC) products to pharmacy chains across Australia and New Zealand. The company is currently establishing a ...